Environmental, Social And Governance Report

Overview

The report covers the Group's 2023 ESG performance across governance, innovation, product quality, talent, low-carbon operations and community welfare. Highlights include six commercialized innovative drugs and approximately 1,000 R&D employees, 100% factory ISO 14001 certification coverage, and a 31.31% reduction in GHG emissions intensity versus 2020. The company also reported approximately RMB 67.13 million in charitable donations and zero work-related fatalities.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services